A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy

Trial Profile

A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Mar 2018

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Nivolumab (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 08 Jan 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Feb 2018.
    • 12 Dec 2017 Results (n=62) assessing the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL), were presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 11 Dec 2017 Interim results (n=62; as of 21 Jul 2017) published in the Blood Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top